Pristinamycin

Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF).

Product information

CAS Number: 270076-60-3

Molecular Weight: 1349.48

Formula: C71H84N10O17

Chemical Name: 21-hydroxy-11,19-dimethyl-10-(propan-2-yl)-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.0³,⁷]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone; N-{3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentaazatricyclo[20.4.0.0⁶,¹⁰]hexacosan-15-yl}-3-hydroxypyridine-2-carboxamide

Smiles: CN1C(CC2C=CC=CC=2)C(=O)N2CCC(=O)CC2C(=O)NC(C2C=CC=CC=2)C(=O)OC(C)C(NC(=O)C2=NC=CC=C2O)C(=O)NC(CC)C(=O)N2CCCC2C1=O.CC1C=CC(=O)NCC=CC(C)=CC(O)CC(=O)CC2=NC(=CO2)C(=O)N2CCC=C2C(=O)OC1C(C)C

InChiKey: MVTQIFVKRXBCHS-FHWPYUEJSA-N

InChi: InChI=1S/C43H49N7O10.C28H35N3O7/c1-4-29-40(56)49-21-12-17-30(49)41(57)48(3)32(23-26-13-7-5-8-14-26)42(58)50-22-19-28(51)24-31(50)37(53)47-35(27-15-9-6-10-16-27)43(59)60-25(2)34(38(54)45-29)46-39(55)36-33(52)18-11-20-44-36;1-17(2)26-19(4)9-10-24(34)29-11-5-7-18(3)13-20(32)14-21(33)15-25-30-22(16-37-25)27(35)31-12-6-8-23(31)28(36)38-26/h5-11,13-16,18,20,25,29-32,34-35,52H,4,12,17,19,21-24H2,1-3H3,(H,45,54)(H,46,55)(H,47,53);5,7-10,13,16-17,19-20,26,32H,6,11-12,14-15H2,1-4H3,(H,29,34)/b;7-5-,10-9-,18-13-

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

In-vitro studies show pristinamycin to inhibit Staphylococci and Streptococci, including Erythromycin highly-resistant organisms, at a concentration of less than or equal to 0.78 mg/l.

In Vivo:

To study Pristinamycin activity in vivo, mice infected IP with C. psittaci. Mortality in the control group was 70%. Three groups of mice received 25 mg/kg, 50 mg/kg and 100 mg/kg Pristinamycin respectively. The antibiotic was active in the 100 mg/kg dosage which is the therapeutic dosage.

Products are for research use only. Not for human use.